# Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT04612751** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 155 (actual)

## Conditions studied

- Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** Datopotamab deruxtecan
- **DRUG:** Durvalumab
- **DRUG:** Carboplatin
- **DRUG:** AZD2936
- **DRUG:** MEDI5752
- **DRUG:** AZD7789

## Key facts

- **NCT ID:** NCT04612751
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-02
- **Primary completion:** 2026-05-04
- **Final completion:** 2026-05-04
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04612751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04612751, "Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04612751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*